Clinical Trial Update: Effects of Saffron on Mild to Moderate Generalized Anxiety Disorder (GAD) [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial is evaluating saffron extract for patients with mild to moderate generalized anxiety disorder; the current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• Saffron extract (Crocus sativus extract)

Snippet

Sponsor: National Nutrition and Food Technology Institute | Conditions: Patients With Mild to Moderate GAD | Phase 2, Phase 3 | Status: UNKNOWN